0000000001140486

AUTHOR

A. Vito Ditta

showing 1 related works from this author

Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for…

2004

BACKGROUND: H 1 -receptor antagonists are considered to be particularly effective in reducing pruritus, and they are therefore recommended as first-line treatment in patients with chronic idiopathic urticaria (CIU). Recently, antileukotriene receptors have been used in patients with CIU, either administered as monotherapy or combined with H 1 -receptor antagonists. OBJECTIVE: We compared the clinical efficacy of 5 mg of desloratadine administered once daily either as monotherapy or combined with a leukotriene antagonist, 10 mg of montelukast daily, and 10 mg of montelukast administered daily as monotherapy for the treatment of patients affected by CIU with placebo. METHODS: One hundred sixt…

AdultCyclopropanesMalemedicine.medical_specialtyHistamine H1 Antagonists Non-SedatingSettore MED/09 - Medicina InternaAdolescentUrticariamedicine.medical_treatmentImmunologyPlacebo-controlled studyRandomized placebo-controlled trial; desloratadine; montelukast; chronic idiopathic urticariaAcetatesSulfidesPlaceboGastroenterologylaw.inventionchemistry.chemical_compoundRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineImmunology and AllergyHumansMontelukastAgedDesloratadineLeukotriene E4Leukotriene receptorbusiness.industrydesloratadineRandomized placebo-controlled trialLoratadineMiddle AgedAntileukotrieneTreatment OutcomechemistryAnesthesiachronic idiopathic urticariaChronic DiseasemontelukastQuinolinesLeukotriene AntagonistsFemalebusinessmedicine.drug
researchProduct